Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia.
Hemospan, a novel hemoglobin-based oxygen carrier and plasma expander, is being developed by Sangart Inc for use as a blood substitute and for the treatment of critical limb ischemia. Hemospan is currently undergoing phase III clinical trials in Europe and phase II clinical trials in the US for use as a blood substitute, and phase II clinical trials in Sweden for critical limb ischemia.
Smani
Younes
Y
Hospital Universitario Virgen-del-Rocío, Caracola Junto Edificio Laboratorios, Laboratorio de Medicina y Cirugía Experimental, Avenida Manuel Siurot, Seville 41013, Spain. Younes.Smani@pharma.uhp-nancy.fr
D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003422:Critical Care; D005121:Extremities / Q000098:blood supply*; D006454:Hemoglobins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D008301:Maleimides; D010101:Oxygen Consumption / Q000187:drug effects*; D010330:Patents as Topic; D011092:Polyethylene Glycols; D012039:Regional Blood Flow / Q000187:drug effects; D013329:Structure-Activity Relationship
D001802:Blood Substitutes; D006454:Hemoglobins; D008301:Maleimides; C493836:maleimide-polyethylene glycol-modified hemoglobin, MP4; D011092:Polyethylene Glycols